NeopharmCO.,LTD.
Financials
Valuation Metrics
NeopharmCO.,LTD.'s Market Cap is ₩3206B. At end of 2025 it was ₩2944B. Ranked #595 of 2,436 in KR market (top 24%), #234 of 1,649 on KOSDAQ (top 14%), #11 of 57 in Household & Personal Products (top 19%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 320.56B KRW | KR#595/2,436 Sec#11/57 |
| Revenue | 136.80B KRW | KR#1,221/2,436 Sec#26/57 |
| Net Income | 29.31B KRW | KR#516/2,436 Sec#14/57 |
| Total Assets | 225.35B KRW | KR#1,204/2,436 Sec#25/57 |
| Net Assets | 192.11B KRW | KR#951/2,436 Sec#19/57 |
| Employees | 171 | KR#1,205/2,436 Sec#27/57 |
| Value | ||
| P/E | 10.94x | KR#764/2,436 Sec#14/57 |
| P/B | 1.67x | KR#1,859/2,436 Sec#42/57 |
| PEG | 0.52x | KR#672/2,436 Sec#19/57 |
| P/S | 2.34x | KR#1,904/2,436 Sec#47/57 |
| EV/EBITDA | 9.75x | KR#591/2,436 Sec#14/57 |
| FCF Yield | 8.49% | KR#677/2,436 Sec#12/57 |
| Profitability | ||
| ROE | 15.26% | KR#228/2,436 Sec#10/57 |
| ROA | 13.01% | KR#109/2,436 Sec#6/57 |
| Op. Margin | 21.71% | KR#127/2,436 Sec#2/57 |
| Revenue Growth | 14.60% | KR#764/2,436 Sec#19/57 |
| Earnings Growth | 20.84% | KR#743/2,436 Sec#22/57 |
| Financial Health | ||
| Debt Ratio | 117.31% | KR#597/2,436 Sec#20/57 |
| Total Debt | 1.06B KRW | KR#1,953/2,436 Sec#47/57 |
| FCF | 27.23B KRW | KR#435/2,436 Sec#10/57 |
| Cash | 31.92B KRW | KR#964/2,436 Sec#23/57 |
| Current Ratio | 5.75x | KR#239/2,436 Sec#6/57 |
| Net Debt/EBITDA | -1.04x | KR#449/2,436 Sec#15/57 |
| Dividend | ||
| Div. Yield | 3.79% | KR#479/2,436 Sec#8/57 |
| Div. Growth | 25.00% | KR#378/2,436 Sec#11/57 |
| Performance | ||
| 1Y Return | 11.73% | KR#508/2,436 Sec#9/57 |
| 1M Return | 7.58% | KR#346/2,436 Sec#17/57 |
| From 52W High | -11.70% | KR#60/2,436 Sec#1/57 |
| 1Y MDD | -28.85% | KR#179/2,436 Sec#1/57 |
| Trading | ||
| Volume | 65,204 shares | KR#1,196/2,436 Sec#30/57 |
| Foreign Own. | 26.68% | KR#142/2,436 Sec#6/57 |
| Per Share | ||
| EPS | 1,829 KRW | KR#423/2,436 Sec#10/57 |
| BPS | 12,282 KRW | KR#804/2,436 Sec#19/57 |
Company Info
Established in 2000, the company is a KOSDAQ-listed cosmetics manufacturer. Its largest shareholder became It's Hanbul after the 2017 merger of Hanbul Cosmetics and It's Skin. The company owns cosmetic brands such as Atopalm, Real Barrier, Derma:B, Tl's, and Zeroid, with 83% domestic sales and 17% exports. Utilizing its proprietary MLE formulation technology, it develops products by understanding skin barrier function and expands its business through new formulation development. Neopharm is headquartered in Yuseong-gu, Daejeon.